Shire nabs much-needed PhIII boost for dry-eye prospect lifitegrast

Just one week after receiving an FDA rejection for dry-eye candidate lifitegrast, Shire ($SHPG) came back on Tuesday with positive Phase III data for the med. The way Bernstein analyst Ronny Gal sees it, "this should be enough for approval," and that means Allergan ($AGN) had better watch out: With Shire's drug taking less time to work and posting efficacy in as many or more trial patients, "our initial thought is that lifitegrast seems somewhat superior" to the Dublin drugmaker's blockbuster Restasis, Gal wrote in a note to clients. Release | More

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The U.S. aesthetics business is booming with fillers and fat freezers garnering interest, and spurring marketing campaigns, post-lockdown COVID-19.